<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122913</url>
  </required_header>
  <id_info>
    <org_study_id>20288</org_study_id>
    <secondary_id>LOXO-TRK-14001</secondary_id>
    <nct_id>NCT02122913</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</brief_title>
  <official_title>A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is done to test the safety of the drug larotrectinib in adult cancer
      patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1,
      NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also
      investigates how the drug is absorbed and processed in the human body. This is the first
      study to test larotrectinib in humans with cancer, for whom no other effective therapy
      exists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be conducted in 2 parts: an initial dose escalation phase of larotrectinib in
      subjects with advanced solid tumors will be followed by an expansion phase in subjects with
      solid tumors having a NTRK fusion.

      The objectives of the study are to determine the safety, pharmacokinetic profile, recommended
      dose and efficacy of orally administered larotrectinib in patients with NTRK fusions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2014</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>25 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>25 months</time_frame>
    <description>The severity of adverse events will be assesssed according to the NCI CTCAE version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>25 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for dose expansion</measure>
    <time_frame>25 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of larotrectinib in plasma (Cmax)</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6 and 8 hours after drug administration on Days 1 and 8 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of larotrectinib in plasma (Tmax)</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6 and 8 hours after drug administration on Days 1 and 8 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of larotrectinib in plasma (t1/2)</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6 and 8 hours after drug administration on Days 1 and 8 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve of larotrectinib in plasma (AUC)</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 6 and 8 hours after drug administration on Days 1 and 8 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-Oncology (RANO) as appropriate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Solid Tumors Harboring NTRK Fusion</condition>
  <arm_group>
    <arm_group_label>Tumor patients_Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor patients_Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor patients_Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor patients_Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor patients_Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor patients_Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor patients_Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).
Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Larotrectinib (Vitrakvi, BAY2757556)</intervention_name>
    <description>BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.</description>
    <arm_group_label>Tumor patients_Dose 1</arm_group_label>
    <arm_group_label>Tumor patients_Dose 2</arm_group_label>
    <arm_group_label>Tumor patients_Dose 3</arm_group_label>
    <arm_group_label>Tumor patients_Dose 4</arm_group_label>
    <arm_group_label>Tumor patients_Dose 5</arm_group_label>
    <arm_group_label>Tumor patients_Dose 6</arm_group_label>
    <arm_group_label>Tumor patients_Expansion</arm_group_label>
    <other_name>LOXO-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with a locally advanced or metastatic solid tumor that has progressed
             or was nonresponsive to available therapies, are unfit for standard chemotherapy or
             for which no standard or available curative therapy exists

          -  Proof of a malignancy harboring a NTRK fusion

          -  Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 and a life expectancy of
             at least 3 months

          -  Adequate hematologic, hepatic, and renal function

        Exclusion Criteria:

          -  Patients with unstable primary central-nervous-system tumors or metastasis, exceptions
             possible

          -  Clinically significant active cardiovascular disease or history of myocardial
             infarction

          -  Active uncontrolled systemic bacterial, viral, or fungal infection

          -  Current treatment with a strong CYP3A4 inhibitor or inducer

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-2602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Neurotrophic tyrosine receptor kinase (NTRK)</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>Fusion Positive</keyword>
  <keyword>TRK fusion</keyword>
  <keyword>TRKA</keyword>
  <keyword>TRKB</keyword>
  <keyword>TRKC</keyword>
  <keyword>ETV6</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

